John Kuruvilla, MD, FRCPC, discussed the positive findings for pembrolizumab compared with brentuximab vedotin in patients with Hodgkin lymphoma in the KEYNOTE-204 study.
Ecaterina Ileana Dumbrava, MD, discusses the rationale for combing BDC-1001, a HER2-targeting TLR7/8 immune-stimulating antibody conjugate with an immune checkpoint inhibitor.
In 2019, there were approximately 30,000 new cases of small cell lung cancer diagnosed in the United States with nearly all cases attributable to cigarette smoking.
For cervical cancer awareness month, Lauren Bollinger, MD, discusses how the increase in research in the field of cervical cancer is driving the progress of treatment.
Antonious Hazim, MD, shares insights on his journey into oncology, his experiences at the Mayo Clinic, and his ongoing research.
Although lung cancer screening rates are currently low, identifying the obstacles and potential solutions may raise the number of screenings in the United States.
Closing out their discussion on the management of blastic plasmacytoid dendritic cell neoplasm, expert panelists look toward the future treatment paradigm.
Chenyu Lin, MD, discusses the significance of a 10-year follow up of a study of patients who underwent allogeneic stem cell transplant with the novel cell therapy omidubicel.
In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.
Although there is tremendous excitement about boundaries of science stretching beyond human imagination, realizing the real-world impact of scientific advancement on the health outcomes of patients provides a reality check on how far we still must go.
In season 4, episode 5 of Targeted Talks, Alice P. Chen, MD, discusses important studies that are investigating treatment options for alveolar soft part sarcoma.
Axel Hauschild, MD, PhD, discusses the key findings from the phase 3 COMBI-AD clinical trial, which demonstrated sustained long-term relapse-free survival benefit with the combination of dabrafenib and trametinib compared with placebo in patients with resected, stage III BRAF V600E/K-mutated melanoma.
Joseph Mikhael, MD, discusses the ongoing impact of daratumumab in the treatment landscape of patients with multiple myeloma.
With updated data for the usefulness of tivozanib, patients with recurrent clear cell renal carcinoma have an effective option for treatment in a treatment landscape previously without many treatment options.